Here's Why The Best Is Yet To Come For Pfizer
Pfizer, Inc. (NYSE:PFE) stock is lagging behind the S&P 500 Index so far in 2017. That's nothing new, though. Pfizer has underperformed the S&P 500 over the past year, the past three years, the past five years, and the past decade.
Despite this less-than-stellar track record, I bought Pfizer stock earlier this year. I'm counting on the drugmaker's future to be better than it's recent past. Here's why I think the best is yet to come for Pfizer.
Despite this less-than-stellar track record, I bought Pfizer stock earlier this year. I'm counting on the drugmaker's future to be better than it's recent past. Here's why I think the best is yet to come for Pfizer.